Navigation Links
Trapping prostate cancer cells to keep them from spreading provides hope
Date:3/10/2011

Tampa, Fla. (March 10, 2011) When prostate cancer stem cells (CSCs) were enclosed in self-assembling nanomaterials made of peptides (SAP), the SAP stopped cancer stem cell colony formation and also stopped the division of cancer cells in laboratory cultures (in vitro). According to the international team of researchers who built and tested the nano-sized traps and published their results in a recent issue of Cell Transplantation (20:1), which is freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , the cancer cells grew and multiplied after they were "liberated" from their SAP prisons.

In their article, the researchers suggested that CSCs may be the origin of prostate tumor metastasis, making them an "ideal target" for inhibiting disease metastasis. The group's previous work in building nanomaterials showed that by using SAPs they were able to control the proliferation, elongation and maturation of cells in vitro.

"In this study, we have shown that prostate CSCs can be placed into stasis for an extended period of time without causing them to differentiate," said study corresponding author Dr. Rutledge Ellis-Behnke of the Heidelberg University-based Nanomedicine Translational Think Tank. "If cells are prevented from migrating away from the treatment, they could be subjected to additional targeting."

For the researchers, the isolation of cancer cells with stem-like characteristics "provides solid evidence" that CSCs may exist within the tumor. Additionally, CSCs may account for some treatment failures when treatments are unable to successfully target cancer stem cells, which may be resistant to chemotherapy drugs. Too, CSCs have been found to be more invasive than non-CSCs. The authors speculated that by injecting the material directly into the tumor, it may be possible to stop the spread of metastatic cells.

The research team also suggested that trapping CSCs in the nanomaterial would allow for loading of the SAP with chemotherapy agents, thus offering an increased effectiveness of a localized treatment when targeted cancer cells were unable to 'escape' their chemical enemies. This approach for treating metastatic hormone refractory prostate cancer (HRPC) - a cancer for which all current therapies fail - may offer hope as a successful treatment.

"The goal of cancer therapy is to reduce the ability of cancer cells to divide and migrate," said Dr. Ellis-Behnke. "Accordingly, we have shown that SAP can completely inhibit a prostate CSC from self-renewal while preserving its viability and stem cell properties."

Their study concluded that SAP may be "an effective nanomaterial for inhibiting cancer progression and metastasis."

"The ability to sequester cancer stem cells in SAP to prevent the spread of a prostate cancer is a big step toward finding effective treatments for cancer," Shinn-Zong Lin, professor of neurosurgery at China University Medical Hospital, Taiwan and chair of the Pan Pacific Symposium on Stem Cell Research where this work was first presented. "It will be of considerable interest to se how this technology develops."


'/>"/>

Contact: David Eve
celltransplantation@gmail.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related medicine news :

1. New twist on potential malaria drug target acts by trapping parasites in cells
2. Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study
3. Newer Drug May Help Prevent Fracture in Men With Prostate Cancer
4. PSA velocity screening for prostate cancer may lead to unnecessary biopsies
5. Change in PSA level does not predict prostate cancer
6. PSA Screening for Prostate Cancer Dips in Large U.S. Health Network
7. HJF signs distribution agreement for antibody to evaluate prostate cancer
8. PSA Test Cut-off Could Signal Low-Risk Prostate Cancer
9. Research presented at 2011 GU Cancers Symposium highlights advances in treatment of prostate cancer
10. Could Hair Loss at 20 Signal Higher Prostate Cancer Risk?
11. Losing hair at 20 is linked to increased risk of prostate cancer in later life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... ... the Snake”: an entertaining and moral-based short story about an unkind snake learning a ... Jr., a husband, father and grandfather who served as a U.S. Marine, U.S. Army ... for children and teens. My goal is to teach kids to use good judgement ...
(Date:8/17/2017)... NC (PRWEB) , ... August 17, 2017 , ... ... dental practice, is adding a new location in Goldsboro, NC to its family ... care that is Riccobene Associates’ trademark starting August 15, 2017. , Riccobene ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... series, proudly announces that it will feature the National Council for Therapeutic Recreation ... for more information. , Established in 1981, NCTRC is a non-profit, international organization ...
(Date:8/17/2017)... MA (PRWEB) , ... August 17, 2017 , ... ... will come together on September 19, 2017 for Anti-Infectives Rx. This off-the-record networking ... B. Martin Conference Center at Harvard Medical School. , Industry leaders and decision ...
(Date:8/17/2017)... GA (PRWEB) , ... August 17, 2017 , ... ... to welcome Dr. Kristi Hebert to its newest location in East ... enthusiastic to have Dr. Hebert come aboard,” said Dr. Mark A. Haber, Georgia Urology’s ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... Aug. 2, 2017   Marshall County Hospital in Benton, Kentucky ... the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for ... kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
Breaking Medicine Technology: